<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../figures/favicon.png" type="image/x-icon">
  <title>HIV/AIDS in Obstetric and Gynecological, Practice, Including PMTCT</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="/style.css">
  <link rel="stylesheet" href="/notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="/index.html">
    <div class="home-navigation">
      M
    </div>
  </a>

  <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="/index.html">Home</a>
      </li>
      <li class="menu__item">
        <a class="menu__link" href="/about-temp2.html">About</a>
      </li>
      
     
      

      <li class="menu__item">
        <a class="menu__link" href="#0">Projects</a>
        <ul class="submenu">
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Surgery</a>
          </li>
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Pediatrics</a>
          </li>
        </ul>
      </li>
    </ul>
  </nav>
  
  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterðŸ’œ</p>
      <span><a href="/contribute.html">Contribute here</a> </span>
    </div>

    <h1>HIV/AIDS in Obstetric and Gynecological, Practice, Including PMTCT</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <label class="trigger outline">
        <input type="checkbox" class="checkbox checkbox--red" /> Show/hide outline
        <div class="msg">
         <ol>
            <li><a href="#header-1">Introduction</a></li>
            <li><a href="#header-2">Laboratory testing for HIV </a></li>
            <li><a href="#header-3">Mode of transmission</a></li>
            <li><a href="#header-4">Natural history of HIV infection</a></li>
            <li><a href="#header-5">HIV/AIDS and women</a></li>
            <li><a href="#header-6">HIV/AIDS and reproduction</a></li>
            <li><a href="#header-7">HIV/AIDS and pregnancy</a></li>
            <li><a href="#header-8">Management of HIV+ pregnant woman</a></li>

         </ol>
        </div>
      </label>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction </a>
          </h2>
        </header>
        <div class='body'>
            <p>HIV class: Lentivirus </p>
            <p>Retrovirus: single stranded RNA </p>

            <figure>
              <img src="/figures/hiv (21).jpg" alt="">
              <figcaption> </figcaption>
            </figure>
            <p>Transcribed to double stranded DNA by reverse transcriptase </p>
            <p>Integrates into host genome </p>
            <p>Can lie dormant within a cell for many years, especially in resting (memory) CD4+ T4 lymphocytes </p>

            <figure>
                <img src="/figures/hiv (1).jpg" alt="">
                <figcaption>Structure of HIV cell </figcaption>
            </figure>

            <p>HIV type (distinguished genetically)â€”</p>
            <ul>
                <li>HIV-1 â€“ worldwide pandemic (current approximately 33.4 M people) </li>
                <li>HIV-2 â€“ isolated in West Africa </li>
            </ul>
            <p>HIV-1 groupsâ€”</p>
            <ul>
                <li>M (major): cause of current worldwide epidemic </li>
                <li>O (outlier) and </li>
                <li>N (Cameroon): rare</li>
            </ul>

            <p>HIV-1 M subgroups (clades)â€” </p>
            <ul>
                <li>Clades differ from each other genetically </li>
                <li>>10 identified (named with letters A to K) </li>
                <li>Descended from common HIV ancestor </li>
                <li>One code tends to dominate in a geographic region </li>
                <li>Different clades have different clinical and biologic behavior </li>
            </ul>

            <h4><span class="special-text">The AIDS epidemic in Nigeria </span></h4>
            <p>Nigeria (tenth largest country in the world, the most populous country in Africa). </p>
            <p>Infection primarily heterosexual transmission. </p>
            <p>The results from 2008  HIV seroprevalence sentinel surveys involving pregnant women attending antenatal clinics by the Federal Ministry of Health showed a national prevalence of 4.6%. -Generalized. </p>

            <h4><span class="special-text">Early history of the epidemic </span></h4>
            <p>1981 Cases of Pneumocystic carinii pneumonia and Kaposi's sarcoma in the USA </p>
            <p>1983 Discovery of the virus. First cases of AIDS in the UK </p>
            <p>1984 Development of antibody test </p>

            <h4><span class="special-text">Sub-Saharan Africa and HIV/AIDS </span></h4>
            <p>Home to 10% of world's population and two thirds of the HIV/AIDS burden </p>
            <p>Accounts for 2/3 of all new infections globally </p>
            <p>Â¾ of all AIDS deaths world-wide in-spite of recent improvements in access to antiretroviral treatment </p>
            <p>>90% of all infant infections through MTCT </p>

            <h4><span class="special-text">HIV Estimates in Nigeria </span></h4>
            <p>No of PLWH- 2.95 million (Male-1.23, Female-1.72 million) </p>
            <p>Annual HIV+ Birth-56, 681 </p>
            <p>Cumulative AIDS Death- 2.99million (Male-1.38, Female-1.61) </p>
            <p>Annual AIDS Death-280,000 (Male-123,000, Female-157,000) </p>
            <p>Number requiring ART- 833,000 (Adult-740,000, Children-92,000) </p>
            <p>New infection 380, 000 (Adult-323,000, Children- 57,000) </p>
            <p>Total AIDS orphaned-2.23million </p>



        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Laboratory testing for HIV </a>
          </h2>
        </header>
        <div class='body'>
            <p>Detectable components or products of viral infection for diagnosisâ€” </p>
            <ul>
              <li>Antibodies-ELISA (reactive/non-reactive), Western blot (positive, negative, Indeterminate)</li>
              <li>Antigen- antigen P24 </li>
              <li>Nucleic acid- polymerase chain reaction</li>
              <li>Whole (viable) virus- viral culture</li>
            </ul>
            <p>ELISA (enzyme Linked immuno-sorbent assay) - tests for a number of antibody proteins in combination.  Very sensitive but not entirely specific. </p>
            <p>Rapid tests- provide results in about 10 minutes. Sensitivity approaches 100%; specificity is >99%.  Positive results need to be confirmed with standard serology. Useful in situations where immediate results are important to management decisions e.g. occupational exposure, STD clinics and emergency rooms. </p>
            <p>Western immuno-blot test- confirmatory test. Very specific for HIV. </p>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Mode of transmission </a>
          </h2>
        </header>
        <div class='body'>
            <p><i>Sexual transmission</i>   </p>
            <p>Body fluids </p>
            <p>Donated organs </p>
            <p><i>Vertical transmission </i></p>
            <ul>
              <li>In utero</li>
              <li>At birth</li>
              <li>Durinng breastfeeding</li>
            </ul>
            <p>Intravenous drug users</p>
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Natural History of HIV Infection </a>
          </h2>
        </header>
        <div class='body'>
            <h4><span class="special-text">Immune suppression </span></h4>
            <ul>
                <li>HIV attacks white blood cells, called CD4 cells that protect body from illness. </li>
                <li>Over time, the body's ability to fight common infections is lost. </li>
                <li>Opportunistic infections occur. </li>
            </ul>

            <figure>
              <img src="/figures/hiv (20).jpg" alt="">
              <figcaption> The HIV life cycle</figcaption>
             </figure>
            <h4><span class="special-text">Direct infection of organ systems </span></h4>
            <ul>
                <li>Brain (HIV dementia) </li>
                <li>GIT (wasting) </li>
                <li>Heart (cardiomyopathy) </li>
            </ul>

            <figure>
                <img src="/figures/hiv (1).gif" alt="">
                <figcaption>HIV-related opportunistic infections </figcaption>
            </figure>

            <h4><span class="special-text">AIDS-defining conditons without laboratory evidence of HIV</span></h4>
            <p>Diseases diagnosed definitivelyâ€”</p>
            <ul>
                <li>Candidiasis: esophagus, trachea, bronchi or lungs </li>
                <li>Cryptococcosis: extrapulmonary </li>
                <li>Cryptosporidiosis with diarrhea persisting > 1 month </li>
                <li>Cytomegalovirus disease other than in liver, spleen, nodes </li>
                <li>Herpes simplex virus (HSV) infection </li>
                <ul>
                    <li>Mucocutaneous ulceration lasting 1 month </li>
                    <li>Pulmonary, oesophageal involvement </li>
                </ul>
                <li>Salmonella septicaemia: recurrent </li>
                <li>HIV wasting syndrome </li>
                <li>Recurrent pneumonia within 1 year </li>
                <li>Invasive cervical cancer </li>
                <li>Kaposi's sarcoma in patient < 60 years of age  </li>
                <li>Primary cerebral lymphoma in patient < 60 years of age</li>
                <li>Lymphoid interstitial pneumonia in child < 13 years of age </li>
                <li>Mycobacterium avium: disseminated. </li>
                <li>Mycobacterium kansasiii: disseminated </li>
                <li>Pneumocystis carinii pneumonia </li>
                <li>Progressive multifocal leukoencephalopathy </li>
                <li>Cerebral toxoplasmosis</li>
            </ul>

            <h4><span class="special-text">Diseases diagnosed presumptively </span></h4>
            <ul>
                <li>Candidiasis: esophagus </li>
                <li>Cytomegalovirus retinitis with visual loss </li>
                <li>Kaposi's sarcoma </li>
                <li>Mycobacterial disease (acid-fast bacilli; species not identified by culture): disseminated </li>
                <li>Pneumocystis carinni pneumonia </li>
                <li>Cerebral toxoplasmosis </li>
            </ul>

            <h4><span class="special-text">AIDS-defining conditions with laboratory evidence of HIV </span></h4>
            <p>Diseases diagnosed definitivelyâ€” </p>
            <ul>
                <li>Recurrent/multiple bacterial infections in child <13 year of age </li>
                <li>Coccidiomycosis - disseminated </li>
                <li>HIV encephalopathy </li>
                <li>Histoplasmosis - disseminated </li>
                <li>Isosporiasis with diarrhea persisting> 1 month </li>
                <li>Kaposi's sarcoma at any age </li>
                <li>Primary cerebral lymphoma: diffuse, undifferentiated B cell type, or unknown phenotype </li>
                <li>Any disseminated mycobacterial disease other than M. tuberculosis </li>
                <li>Mycobacterial tuberculosis at any site  </li>
            </ul>

            <h4><span class="special-text">Summary of Natural History </span></h4>
            <p>HIV multiplies inside the CD4 cells, destroying them. </p>
            <p>As CD4 cell count decreases and viral load increases, the immune defenses are weakened. </p>
            <p>People infected with HIV become vulnerable to opportunistic infections. </p>
            <p>HIV is a chronic viral infection with no known cure. </p>
            <p>Without ARV treatment, HIV progresses to symptomatic disease and AIDS. </p>

        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>HIV/AIDS and women</a>
          </h2>
        </header>
        <div class='body'>
            <p>HIV started as disease of MSM </p>
            <p>Rapid heterosexual spread to women. </p>
            <p>Steady rise in prevalence among women since early 1980s </p>
            <p>Women are 50% of adult PLWHA worldwide and 60% of adult PLWHA in Africa </p>
            <p>HIV continues to be progressively feminized </p>

            <h4><span class="special-text">Women are Particularly Vulnerable to Heterosexual Transmission: Why? </span></h4>
            <p>Large mucosal exposure to semen  </p>
            <p>Biology of the HIV virus</p>
            <p>Poverty / Low socio-economic status </p>
            <ul>
                <li>High prevalence of non-consensual sex </li>
                <li>Sex without condom use </li>
                <li>Unknown or high-risk behavior of partners </li>
                <li>Young women with much older partners </li>
            </ul>

            <h4><span class="special-text">Progression of HIV to AIDS in Women </span></h4>
            <p>Viral load is lower in women than men but rate of progression to AIDS is similar </p>
            <p>HIV-infected women have shorter survival times than men (33% more likely to die than men) </p>
            <p>Baseline serum albumin: a strong predictor of 3 year survival </p>
            <p>Higher C-reactive protein (>0.4mg/dl): associated with shorter survival </p>

            <h4><span class="special-text">Women-Specific Symptoms of HIV Infection </span></h4>
            <p>Vaginal yeast infection </p>
            <ul>
                <li>Persistent and more difficult to treat </li>
                <li>Fluconazole is drug of choice. </li>
                <li>Weekly fluconazole can safely prevent oropharyngeal and vaginal, but not esophageal yeast infection </li>
            </ul>
            <p>Bacteria vaginosis, Gonorrhoea, Chlamydia, Trichomoniasis</p>
            <p>Herpes simplex virus ulceration</p>
            <p>Idiopathic genital ulceration (unique manifestation of HIV)</p>
            <p>HPV infection/genital warts</p>
            <p>Cervical dysplasia/cervical cancer</p>
            <p>PID (more common and more aggressive)</p>
            <p>Menstrual irregularities (more likely to be amenorrheic)</p>

        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>HIV/AIDS and reproduction </a>
          </h2>
        </header>
        <div class='body'>
           <p>With Advent of Potent ARVs: </p>
           <ul>
            <li>The HIV-infected are living longer </li>
            <li>HIV now a manageable chronic illness. </li>
            <li>HIV affected couples desire to have children </li>
            <li>Affected couples require information to make informed reproduction decisions </li>
           </ul>
           <p>Sero-discordant Couples; Concerns </p>
           <ul>
              <li>Overall risk of heterosexual transmission is low</li>
              <li>Male to female transmission is significantly higher than the risk of female to male transmission.</li>
              <li>Transmission is increased with:</li>
              <ul>
                <li>Higher plasma viral load in infected partner</li>
                <li>Presence of other STIs in either partner</li>
              </ul>
           </ul>
           <p><i>Concerns with sero-discordant couples</i></p>
           <ul>
            <li>Risk of HIV transmission to un-infected partner </li>
            <li>HIV transmission to the child </li>
            <li>Cost of assisted reproduction techniques. </li>
           </ul>
           <p>Sero-concordant Couples </p>
           <ul>
            <li>Consistent safer sex (condom) advised </li>
            <ul>
                <li>Prevent super-infection, especially with drug- resistant strains </li>
                <li>Prevent infection with other STIs e.g. HCV, HBV </li>
                <li>Prevent new-infection during pregnancy </li>
            </ul>
           </ul>

           <h4><span class="special-text">Suggested Pre-conception Steps </span></h4>
           <ul>
            <li>Disclosure of sero-status </li>
            <li>Practicing safe sex </li>
            <li>Preconception counseling: </li>
            <ul>
                <li>Discuss risk to partner and baby </li>
                <li>Current and future health of infected partner(s) </li>
                <li>HIV testing pre and post-pregnancy </li>
            </ul>
            <li>Absence of an active AIDS-defining illness </li>
            <li>CD4 count >350 and viral load < 50,000 copies/ml </li>
            <li>Patients receiving antiretroviral therapy </li>
            <ul>
              <li>HIV RNA level < 400 copies/ml </li>
              <li>Regimen without teratogenic drugs (Elovirenz, amprenavir) </li>
              <li>Adequate therapy for at least 1 year </li>
            </ul>
           </ul>
           <p>Women </p>
           <ul>
            <li>Endocervical swab (ECS) culture, Pap smear, Pelvic USS, Serum FSH < 15MIU/ml, HSG </li>
           </ul>
           <p>Men </p>
           <ul>
            <li>Semen analysis </li>
           </ul>
           <p>Men and Women </p>
           <ul>
            <li>CBC, LFT, Hepatitis virus screening, pelvic examination </li>
            <li>Full screening for HIV, other STIs and TB. </li>
           </ul>

           <h4><span class="special-text">Assisted Reproduction Techniques </span></h4>
           <p>Self-insemination </p>
           <ul>
            <li>Low cost option for sero-discordant couples (woman infected, man un-infected) </li>
            <li>Use of freshly ejaculated semen </li>
            <li>Dispensed by a standard syringe (without the needle) or a disposable plastic Pasteur pipette </li>
           </ul>

           <h4><span class="special-text">Timed Intercourse </span></h4>
           <ul>
            <li>Both partners undergo infertility work-up </li>
            <li>Methods of identifying fertility window: BBT, Calendar calculation, Ovarian follicle tracking by USS, Urine LH and Billings method (cervical and vaginal discharge) </li>
            <li>Gilling-Smith(2000) reported 4% transmission rate in 92 sero-discordant couples. Sero-conversion was restricted only to partners who reported inconsistent condom use outside the 'fertile periodâ€™. </li>
           </ul>


        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'>HIV/AIDS and pregnancy  </a>
          </h2>
        </header>
        <div class='body'>
           <p>Population-based studies of fertility in women with HIV-1 infection in Africa found that pregnancy rates were lower and pregnancy loss was more common in HIV-infected women </p>
           <p>Pregnancy does not accelerate decline in CD4 cells </p>
           <p>Pregnancy has little to no effect on HIV progression in asymptomatic women or women with early infection.</p>
           <p>More rapid progression in women with late stage HIV infection</p>
           <p>HIV has little effect on pregnancy in the developed world</p>
           <p>Adverse effect in African studies</p>
           <ul>
            <li>Spontaneous abortion</li>
            <li>Intrauterine growth restriction</li>
            <li>Preterm birth</li>
            <li>Low birth weight</li>
            <li>Pneumonia</li>
            <li>UTI</li>
            <li>Ectopics</li>
            <li>PROM</li>
            <li>Infections</li>
            <li>Abruptio placenta</li>
            <li>Still birth</li>
           </ul>

           <h4><span class="special-text">Issues to consider in Pregnancy </span></h4>
            <p>Pregnancy may influence infection because of pregnancy related suppression of cellular immunity </p>
            <p>CD4 & CD8 percentages are stable during pregnancy </p>
            <p>Pregnancy rates among HIV positive women who have not yet developed AIDs are comparable with those among uninfected women. Women with AIDs with opportunistic infection are considered less likely to become pregnant. </p>
            <p>No clinically significant changes in pregnancy or postpartum </p>
            <p>Overall pregnancy does not seem to accelerate HIV infection. </p>

            <section id='heading-7-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-7-1'>Mother to Child Transmission (MTCT) of HIV </a>
                  </h3>
                </header>
                <div class='body'>
                   <p>Over 56,000 children are newly infected with HIV in Nigeria each year </p>
                   <p>Nigeria alone contributes 30% of global new infant infections through MTCT </p>
                   <p>In contrast: </p>
                   <ul>
                    <li>USA & Western Europe - 1000 </li>
                    <li>Australia & New Zealand 100 </li>
                   </ul>
                   <p>Between 15% and 40% of babies born to HIV positive mothers acquire the infection in the absence of intervention. </p>

                   <h4><span class="special-text">Key determinants: </span></h4>
                   <ul>
                    <li>High maternal plasma viral load </li>
                    <li>Length of exposure to breast milk </li>
                   </ul>

                   <figure>
                    <img src="/figures/hiv (10).png" alt="">
                    <figcaption>Fig. MTCT rates of HIV in several studies worldwide (no intervention) </figcaption>
                   </figure>

                   <p>MTCT of HIV can occur </p>
                   <ul>
                    <li>In-utero [5-10%] </li>
                    <li>During labour/delivery [10-20%] </li>
                    <li>Through breastfeeding [5-20%] </li>
                   </ul>

                   <p>MTCT of HIV (Kinshasa, DRC)</p>
                   <ul>
                    <li>In-utero [23%] </li>
                    <li>Intrapartum [65%] </li>
                    <li>Postpartum [12%] </li>
                   </ul>

                   <p>MTCT of HIV (French collaborative study)</p>
                   <ul>
                    <li>In-utero, late in pregnancy [35%] </li>
                    <li>Around the time of labor [65%] </li>
                   </ul>

                   <figure>
                    <img src="/figures/hiv (11).png" alt="">
                    <figcaption> Fig. Mother-Infant HIV transmission in hypothetical cohort of 100 children of HIV+ mothers pg 42</figcaption>
                   </figure>

                   <h4><span class="special-text">Factors affecting mother-to-child transmission of HIV </span></h4>
                   <p>Viral </p>
                   <ul>
                    <li>Viral load </li>
                    <li>Viral genotype and phenotype </li>
                    <li>Viral resistance </li>
                   </ul>

                   <p>Maternal </p>
                   <ul>
                    <li>Maternal Immunological status </li>
                    <li>Maternal nutritional status </li>
                    <li>Maternal clinical status </li>
                    <li>Behavioural factors (Smoking, Alcohol, and Injection drug use) </li>
                    <li>HIV infection acquired during pregnancy or breastfeeding </li>
                    <li>Genital tract infections (STIs, Chorioamnionitis) </li>
                   </ul>

                   <p>Obstetrical </p>
                   <ul>
                    <li>Prolonged rupture of membranes (>4 hours) </li>
                    <li>Mode of deliveryâ€” vaginal delivery is higher risk than CS</li>
                    <li>Intrapartum haemorrhage </li>
                    <li>Obstetrical procedures </li>
                    <ul>
                        <li>Chorionic villus sampling</li>
                        <li>Amniocentesis</li>
                        <li>External cephalic version</li>
                        <li>Etc</li>
                    </ul>
                    <li>Invasive fetal monitoring </li>
                   </ul>

                   <figure>
                    <img src="/figures/hiv (12).png" alt="">
                    <figcaption> Fig. Relationship between duration of membranes rupture and mother to child transmission.</figcaption>
                   </figure>

                   <p>Fetal </p>
                   <ul>
                    <li>Prematurity </li>
                    <li>Genetic </li>
                    <li>Multiple pregnancy </li>
                    <li>Placental malaria </li>
                   </ul>

                   <p>Infant </p>
                   <ul>
                    <li>Breastfeeding </li>
                    <li>Gastrointestinal tract factors </li>
                    <li>Immature immune system </li>
                   </ul>

                   <p>Risk Factors for Postnatal Transmission </p>
                   <ul>
                    <li>Younger maternal age, lower parity </li>
                    <li>Maternal sero-conversion during lactation </li>
                    <li>Maternal immune status (CD4) </li>
                    <li>Plasma and breast milk viral load </li>
                    <li>Duration of breastfeeding </li>
                    <li>Breast health: </li>
                    <ul>
                        <li>Mastitis (clinical and subclinical)</li>
                        <li>Breast abscess </li>
                        <li>Cracked nipples </li>
                    </ul>
                    <li>Infant factors (oral thrush) </li>
                    <li>Pattern infant feeding - exclusive vs mixed </li>
                   </ul>

                   <figure>
                    <img src="/figures/hiv (1).png" alt="">
                    <figcaption> Fig. Pattern of Infant Feeding and HIV Transmission in Breastfeeding Children, South Africa </figcaption>
                   </figure>

                   <h4><span class="special-text">Components of PMTCT (UNGASS) </span></h4>
                   <ol>
                    <li>Primary prevention of HIV infection in women of reproductive age </li>
                    <li>Prevention of unintended pregnancies among women infected with HIV </li>
                    <li>Prevention of HIV transmission from women infected with HIV to their babies </li>
                    <li>Provision of treatment, care, and support to women infected with HIV, their infants, and their families </li>
                   </ol>

                   <h4><span class="special-text">Strategies of PMTCT </span></h4>
                   <p>Prevention of HIV among women of childbearing age </p>
                   <ul>
                    <li>Abstinence </li>
                    <li>Being faithful </li>
                    <li>Condom use </li>
                    <li>Safe blood transfusion </li>
                    <li>Safety of sharps </li>
                   </ul>
                   <p>Prevention of unintended pregnancy among HIV-positive women </p>
                   <ul>
                    <li>Family planning counseling and services </li>
                    <li>Abortion/post abortion services </li>
                   </ul>
                   <p>Prevention of MTCT </p>
                   <ul>
                    <li>Universal ANC patronage </li>
                    <li>HIV Counseling & testing (opt-out approach) </li>
                    <li>Anti-retroviral drug prophylaxis/therapy </li>
                    <li>Safe obstetric & delivery practices </li>
                    <li>Infant feeding counseling and support </li>
                   </ul>

                   <p>Provision of care & support to HIV-infected women, their infants & families </p>
                   <ul>
                    <li>Mother/family's HIV care/treatment </li>
                    <li>Early infant diagnosis & treatment </li>
                    <li>Support for OVC </li>
                    <li>Strengthening of social/economic/nutritional support </li>
                   </ul>

                   <p>Prevention of new infections in young women </p>
                   <ul>
                    <li>Improvement of women's status in society </li>
                    <li>Provision of information about HIV/AIDS and its prevention </li>
                    <li>Promotion of safer sex (barrier methods) </li>
                    <li>Adequate treatment of STIs. </li>
                   </ul>

                   <p>Behavioral interventions </p>
                   <ul>
                    <li>Reduction in frequency of unprotected sex during pregnancy. </li>
                    <li>Reduction in the number of sexual partners during pregnancy. </li>
                    <li>Lifestyle changes; avoidance of drug use and smoking in pregnancy. </li>
                   </ul>

                   <p>Therapeutic interventions </p>
                   <ul>
                    <li>Antiretroviral therapy </li>
                    <li>Treatment of STIs. </li>
                   </ul>

                   <p>Obstetric interventions </p>
                   <ul>
                    <li>Avoidance of invasive/traumatic tests and procedures. </li>
                    <li>Caesarean section delivery. </li>
                   </ul>

                   <p>Modification of infant feeding practice </p>
                   <ul>
                    <li>Formula feeding exclusively [When AFAS- Acceptable, Feasible, Affordable, Sustainable, Safe]. </li>
                    <li>Breastfeeding exclusively for first 6 months. </li>
                    <li>Heat treatment of expressed breast milk </li>
                    <li>Avoidance of mixed feeding </li>
                    <li>Prophylactic HAART during breastfeeding </li>
                   </ul>

                   <p>Infant therapy </p>
                   <ul>
                    <li>Antiretroviral prophylaxis. </li>
                   </ul>

                   <h4><span class="special-text">Specific interventions </span></h4>
                   <ul>
                    <li>Screen and treat STI in pregnant women </li>
                    <li>Use of antiretroviral drugs </li>
                    <li>Safe delivery practices </li>
                    <li>Safe infant feeding practices </li>
                   </ul>

                   <h4><span class="special-text">The goal of PMTCT </span></h4>
                   <p>To prevent the transmission of HIV from mother to child </p>
                   <p>To mitigate the impact of HIV/AIDS on infected and affected individuals </p>

                   <h4><span class="special-text">A PMTCT- plus program  </span></h4>
                   <ul>
                    <li>VCT </li>
                    <li>ANC </li>
                    <li>Delivery care </li>
                    <li>PP care </li>
                    <li>Infant care </li>
                    <li>Long term follow up </li>
                   </ul>

                   <h4><span class="special-text">Support services </span></h4>
                   <p>Support groups </p>
                   <p>Micro-credit </p>
                   <p>Home visits </p>


                </div>
            </section>

            <section id='heading-7-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-7-2'>National PMTCT Program </a>
                  </h3>
                </header>
                <div class='body'>
                    <h4><span class="special-text">Objective of National PMTCT Program </span></h4>
                    <p>To reduce the proportion of infants who acquire HIV from their mothers by 50% and to mitigate the impact of the infection on women and their families </p>
                    <figure>
                        <img src="/figures/hiv (7).png" alt="">
                        <figcaption>Fig. Partner Disclosure of HIV Status by Sero Positive Mothers in Jos Nigeria  </figcaption>
                    </figure>

                    <h4><span class="special-text">National PMTCT Protocol </span></h4>
                    <p>ANC clinic and side laboratory:</p>
                    <ul>
                      <li>Group counselling</li>
                      <li>Routine offer of HIV testing with options to decline</li>
                      <li>Testing algorithm using 2 Rapid tests and a tie breaker to confirm positive cases</li>
                      <li>Individual post test counselling</li>
                    </ul>

                    <p>Post test counselling for HIV positive women</p>
                    <ul>
                      <li>Birth options and other preventive measures</li>
                      <li>Counselled on ARV interventions</li>
                      <li>Counselled on infant feeding options</li>
                      <li>Nneed to deliver in hospital</li>
                    </ul>
                    
                    <p>Post test for HIV Negative </p>
                    <ul>
                        <li>Counsel on 'window period' </li>
                        <li>Consider re-testing in labor </li>
                        <li>Offer syndromic STI management </li>
                        <li>Importance of partner testing </li>
                    </ul>

                    <figure>
                        <img src="/figures/hiv (13).png" alt="">
                        <figcaption>Fig. evolution of efficacy of ARV prophylaxis </figcaption>
                    </figure>

                    <p>Pediatric Follow up: </p>
                    <ul>
                        <li>Infant feeding counseling & support </li>
                        <li>Infant immunizations & growth monitoring </li>
                        <li>Infant diagnosis (from 6 weeks) and treatment </li>
                    </ul>
                    <p>Post natal Clinic: </p>
                    <ul>
                        <li>Evaluation of Mom for ARV and refer accordingly </li>
                        <li>Family Planning </li>
                        <li>Cervical Screening </li>
                        <li>Partner testing and referral accordingly </li>
                    </ul>

                    <h4><span class="special-text">Infant feeding of choice </span></h4>
                    <p>Breast feeding?</p>
                    <p>Breast milk substitutes- ????? AFASS </p>
                    <p>BMS a right issue </p>
                    <p>Diarrhea vs HIV </p>

                    <h4><span class="special-text">Breastfeeding and transmission </span></h4>
                    <p>There is a greater risk within the first week â†’ months </p>
                    <p>4-6% risk for week 6â†’ 6 months </p>
                    <p>Late breastfeeding is associated with a low continuous rate of transmission of 3.2%/year </p>
                    <p>Factors associated with transmission </p>
                    <ul>
                        <li>Low vitamin A levels </li>
                        <li>Mastitis </li>
                        <li>Low IgA </li>
                    </ul>

                    <h4><span class="special-text">Challenges of PMTCT</span></h4>
                    <ul>
                        <li>Poor coverage </li>
                        <li>Inadequate supplies </li>
                        <li>Poor capacity </li>
                        <li>Nil motivation </li>
                        <li>Stigma/discrimination </li>
                        <li>Service problem </li>
                        <li>Unsupervised delivery</li>
                        <li>Upgrade of services </li>
                        <li>Universal precaution </li>
                        <li>Infant feeding </li>
                        <li>ARV/adherence </li>
                        <li>MTCT plus </li>
                        <li>Care of orphan </li>
                        <li>Long term follow-up </li>
                    </ul>

                    <h4><span class="special-text">Recommendations </span></h4>
                    <ul>
                        <li>Pregnancy is an indication for ARV </li>
                        <li>ANC becomes portal of entry </li>
                        <li>Combination therapy-gold standard is HAART </li>
                        <li>Universal access /PMTCT in ANC </li>
                        <li>ARV in continuum of care </li>
                        <li>Shared care </li>
                        <li>Data management </li>
                        <li>Monitoring/evaluation </li>
                    </ul>

                        <blockquote>
                            <p>There is no shame in being HIV+ but there is shame in rejecting the HIV+ patient. </p>
                            <p>HIV can affect anybody including our friends and relations </p>
                            <p>HIV+ patients deserve our care, love and support.</p>
                            <p>â€”Nelson Mandela </p>
                        </blockquote>


                </div>
            </section>

            <section id='heading-7-3'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-7-3'>ART in Pregnancy</a>
                  </h3>
                </header>
                <div class='body'>
                   <p>Pregnancy in the HIV seropositive woman is an indication for prophylactic ART irrespective of CD4 count, viral load or clinical stage of the disease.</p>
                   <p>The time of commencement and choice of ART in HIV seropositive pregnant women depends on the clinical setting.</p>
                   <p>Where possible, ART should be provided in consultation with an experienced physician.</p>

                   <h4><span class="special-text">Goals of ARV </span></h4>
                    <ul>
                        <li>Maximize long term viral suppression </li>
                        <li>Minimize risk of drug resistance </li>
                        <li>Minimize long term toxicity </li>
                        <li>Maximize capacity of immune reconstitution </li>
                        <li>Optimize clinical outcome/quality of life </li>
                        <li>Minimize cost of care </li>
                        <li>Eliminate MTCT and synergize with long term public health efforts </li>
                    </ul>

                    <h4><span class="special-text">Use of ARVs</span></h4>
                    <ul>
                        <li>PACTGâ€”076â€”(1000 USD)</li>
                        <li>Bangkok breast feeding AZT study</li>
                        <li>AZT in breast feeding women</li>
                        <li>Petra studyâ€” AZT + 3TC (Lamivudine)</li>
                        <li>Nevirapineâ€”(2 USD)</li>
                        <li>AZT + NVP </li>
                        <li>AZT + ddI (NVP + 3TC)</li>
                        <li>HAART</li>
                    </ul>

                    <h4><span class="special-text">Perinatal transmission studies</span></h4>
                    <p>Regimens that lower viral load reduce the risk of transmission.</p>
                    <p>No threshold value of viral load is below which riks of transmission is zero</p>
                    <p>Benefit of treatment seen even among wwomen with VL < 1000 copies/ml</p>
                    <p>Observational studies suggest greater reductions in transmission with tripple combination therapy</p>

                    <h4><span class="special-text">Vertical transmission</span></h4>
                    <p>Background transmission risk: 30â€”45%</p>
                    <ul>
                      <li>15â€”30% risk during pregnancy and delivery</li>
                      <li>10â€”20% additional risk post-partum via breastfeeding</li>
                    </ul>

                    <p>Transmission risk with interventions:</p>
                    <ul>
                      <li>20â€”25% risk with no breastfeeding</li>
                      <li>15â€”25% risk with short course ARV + breastfeeding</li>
                      <li>5â€”15% risk with short course ARV, no BF</li>
                      <li>1â€”5% risk with combination short course ARVs, no BF</li>
                      <li>1% 2 or 3 ARVs + C-section, no BF</li>
                    </ul>
                    <h4><span class="special-text">NRTI Mechanism of Action </span></h4>
                    <p>NRTIs must first undergo intracellular phosphorylation to be active </p>
                    <p>NRTIs inhibit the viral reverse transcriptase enzyme </p>
                    <ul>
                        <li>Enzyme responsible for transcribing viral RNA into double stranded DNA </li>
                    </ul>
                    <p>NNRTIs also inhibit the viral reverse transcriptase enzyme but have a different mechanism of action compared to NRTIs </p>
                    <p>NNRTIs bind directly to the reverse transcriptase enzyme </p>
                    <p>Viral RNA is not converted to double stranded DNA </p>

                    <h4><span class="special-text">PI Mechanism of Action </span></h4>
                    <p>Protease enzyme is responsible for cleaving (cutting up) larger polyproteins into structural proteins and reverse transcriptase enzyme Protease is needed to form a fully mature, functional virus that is able to replicate and produce more virus </p>
                    <p>Protease inhibitors prevent this enzyme from doing its job in the later steps of the viral life cycle </p>

                  
                </div>
              </section>
        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'> Management of the HIV Positive Pregnant woman </a>
          </h2>
        </header>
        <div class='body'>
           <ul>
            <li>Limited ability of health system Lack diagnostic techniques for: </li>
            <ul>
                <li>HIV </li>
                <li>Opportunistic infections, STIs </li>
                <li>Viral load </li>
                <li>Surrogate markers for progression of HIV </li>
            </ul>
            <li>Should be jointly managed by HIV Specialist, an obstetrician, midwife and pediatrician </li>
            <li>Early booking </li>
            <li>Screen for Hepatitis B syphilis and common STIs, cervical cytology </li>
            <li>Rest of ANC remains the same </li>
           </ul>

           <h4><span class="special-text">Ante-natal care </span></h4>
           <ul>
            <li>Health education </li>
            <li>Voluntary counselling and testing (VCT) </li>
            <li>Avoid invasive diagnostic procedures </li>
            <li>Watch for telltale signs </li>
            <li>TB, thrush, anemia</li>
            <li>Nutritional support </li>
            <li>Treat malaria </li>
            <li>Fe/FA supplement </li>
            <li>FP </li>
           </ul>

           <h4><span class="special-text">Care in labor and delivery </span></h4>
           <ul>
            <li>Avoid ARM/PROM/fetal scalp blood sampling </li>
            <li>Aavoid procedures such as ECV </li>
            <li>Universal precautions should be applied </li>
            <li>Avoid routine episiotomy </li>
            <li>Forceps preferable to vacuum </li>
            <li>Elective C/S beneficial </li>
            <li>Prophylactic antibiotics </li>
           </ul> 

           <h4><span class="special-text">Intrapartum </span></h4>
           <ul>
            <li>Elective Caesarean section </li>
            <ul>
                <li>Combined with antiretrovirals </li>
            </ul>
            <li>Double gloving </li>
            <li>Use of blunt needles and tissue holding forceps </li>
            <li>Fetal membranes should be left unruptured </li>
            <li>Avoid invasive procedures </li>
            <ul>
                <li>Amniocentesis </li>
                <li>Fetal scalp electrodes </li>
                <li>Amniotomy </li>
                <li>Peripartum cord blood sampling </li>
            </ul>
            <li>All procedures including assisted delivery increase risk of MTCT </li>
            <li>Early cord clamping and early bathing of the baby </li>
           </ul>

           <h4><span class="special-text">Postpartum Care </span></h4>
           <ul>
            <li>Women should not be isolated </li>
            <li>Universal precautions should be practiced Proper disposal of contaminated sanitary towels, lochia, dressings and drains </li>
            <li>Decontaminate toilet - seats and ward floors with sodium hypochlorite solution </li>
            <li>Postnatal care and counseling for woman and partner on safer sexual practice and appropriate contraceptive plans: condom use. </li>
           </ul>

           <figure>
            <img src="/figures/hiv (8).png" alt="">
            <figcaption> Fig. Antiretroviral agents </figcaption>
           </figure>

           <figure>
            <img src="/figures/hiv (19).png" alt="">
            <figcaption>NRTIs </figcaption>
           </figure>

           <figure>
            <img src="/figures/hiv (18).png" alt="">
            <figcaption>NNRTIs </figcaption>
           </figure>

           <figure>
            <img src="/figures/hiv (17).png" alt="">
            <figcaption>Fusion inibitor </figcaption>
           </figure>

           <figure>
            <img src="/figures/hiv (15).png" alt="">
            <figcaption>Pregnant mother not eligible for HAART for her own disease </figcaption>
           </figure>

           <figure>
            <img src="" alt="">
            <figcaption>NRTI combination </figcaption>
           </figure>

           <figure>
            <img src="/figures/hiv (14).png" alt="">
            <figcaption>Contraindicated NRTI Combinations   </figcaption>
        </figure>

        <h4><span class="special-text">Recommendations</span></h4>
        <p>In pregnant women with confirmed HIV serostatus, initiation of ART for her own health is recommended for all HIV-infected pregnant women with CD4 cell count < 350 cells/mm<sup>3</sup>, irrespective of WHO clinical staging; and for all HIV infected pregnant women in WHO clinical stage 3 or 4, irrespective of CD4 cell count. </p>
        <p>HIV-infected pregnant women in need of ART for their own health should start ART irrespective irrespective of gestational age and continue throughout pregnancy, delivery and thereafter. (Strong recommendation, moderate quality evidence).</p>
        <p>All HIV-infected pregnant women who are not in need of ART for their own health require an effective ARV prophylaxis strategy to prevent HIV transmission to the infant. ARV prophylaxis should be started from as early as 14 wweeks gestation (second trimester) or as soon as possible when women present late in pregnancy, in labor or at delivery. (Strong recommendation, low quality evidence).</p>

           <h4><span class="special-text">The HIV exposed infant </span></h4>
           <p>All infants born to HIV-infected women should receive daily NVP from birth until 6 weeks of age. </p>
           <p>Thereafter, exclusively breastfed infants whose mothers are NOT on HAART should continue receiving daily NVP until one week after stopping breastfeeding. (Strong recommendation, moderate quality evidence).</p>


           <h4><span class="special-text">Co-trimazole abd malaria prophylaxis</span></h4>
          <p>Routine Co-trim prophylaxis for CD4 350 and below.</p>
          <p>Malaria prophylaxis: 3 doses of sulphadoxine-pyrimethamine (Fansidar) from 2nd trimester at least 4 weeks apart.</p>
          <p>Patients on Co-trim do not need S-P for malaria prophylaxis during pregnancy.</p>

          <h4><span class="special-text">Cesarean section to reduce perinatl HIV transmission</span></h4>
          <p>C/S reduces transmission in women with unknown VL who are not on ART or are receiving only ZDV.</p>
          <p><span class="underlined--offset">ACOG recommended C/S for pregnant women with VL > 1000 cells/ml near time of delivery.</span></p>
          <p>Unclear whether scheduled C/S offers any benefit to women on ART with VL â‰¤ 1000 copies/ml, given the low transmission rate.</p>
          <p>C/S should be scheduled at 38 weeks, determined by the best clinical estimates.</p>
          <p>Complications of C/S somewhat more frequent than in HIV-uninfected women, increased in immunocompromized women.</p>

          <h4><span class="special-text">Breastfeeding and HIV infection</span></h4>
          <p>HIV in 60% of milk samples</p>
          <p>Breastfeeding of 24 months= additional 16% MTCT rates.</p>
          <p>BF reduces long term overall efficacy of short course AZT.</p>

          <h4><span class="special-text">Choice of infant feeding</span></h4>
          <p>Exclusive formula feeding</p>
          <p>Exclusive breast feeding</p>
          <p>Pretoria pasteurization- heat expressed breast milk to 62.5Â°C</p>
          <p>Cow or goat milk</p>
          <p>RT have shown a 44% reduction in VT in formula-fed infants.</p>
          <p>although many patients chose BMS, they face tremendous opposition in a society that believes breast-milk is best and that something is fundamentally wrong with a woman who does not breastfeed her baby.</p>
          <p>Problems of formula feeding</p>
          <ul>
            <li>Diarrhea</li>
            <li>Malnutrition</li>
            <li>Sepsis</li>
            <li>Occasionally, death</li>
          </ul>
          <p>Multivitamins resulted in large and significant reductions in the risk of </p>
          <ul>
            <li>Fetal death</li>
            <li>Low birth weight</li>
            <li>Severe prematurity</li>
          </ul>
          <p>Significant and sustained improvements in CD4 and CD8 cell counts.</p>
        </div>
      </section>

 </section>

      </section>

      <div class="contact">
        <hr style="margin: 3rem 0;">

        <p>Send us a <a href="mailto:obgyn.materia@gmail.com"><span class="special-text-2">mail</span></a> at 
         <br> obgyn.materia@gmail.com.</p>
        <p>Or send your comments, corrections, explanations/clarifications and requests/suggestions to our 
         <br> <a href="" class="special-text-2" style="text-decoration: none;">WhatsApp group</a>.</p>
      </div>
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p>obgyn.materia</p>
          
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="/main.js"></script>
</body>
</html>
